All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

98

Reset

98 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • ZG006Phase 38 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor

  • OpevesostatMK-5684, ODM-208Phase 37 trials

    Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • XNW5004EZH2iPhase 37 trials

    Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1

  • tinengotinibTT-00420Phase 36 trials

    TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)

  • aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials

    Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • DB-1311BNT324Phase 34 trials

    BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors

  • PasritamigJNJ-78278343Phase 34 trials

    Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials

    Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)

  • 64Cu-SAR-bisPSMAPhase 33 trials

    Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms

  • CyclophosphamidPhase 33 trials

    Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer

  • Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials

    Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

  • MevrometostatPF-06821497Phase 33 trials

    Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer

  • 177Lu-NYM032Phase 32 trials

    Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer

  • AAA817[225Ac]Ac-PSMA-617Phase 32 trials

    Novartis · Prostate Cancer

  • ARDTPhase 32 trials

    Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

  • ARPI: EnzalutamideARPI abirateronePhase 32 trials

    Novartis · Metastatic Castration Resistant Prostate Cancer (mCRPC), Prostate Cancer

  • Copper Cu 64 PSMA I&TPhase 32 trials

    Curium US LLC · Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate

  • PF-07248144Phase 32 trials

    Pfizer · Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • RezvilutamidePhase 32 trials

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  • XaluritamigAMG 509Phase 32 trials

    Amgen · Metastatic Castration-resistant Prostate Cancer

  • BMS-986365Phase 31 trial

    Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer

  • DeutenzalutamidePhase 31 trial

    AstraZeneca · Metastatic Castration-resistant Prostate Cancer

  • FuzuloparibPhase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • HRS-4357Phase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

  • QLG1080Phase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Prostate Cancer

  • RinzimetostatORIC-944Phase 31 trial

    ORIC Pharmaceuticals · Metastatic Castration Resistant Prostate Cancer

  • PalacaparibAZD9574Phase 25 trials

    AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials

    Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer

  • luxdegalutamideJSB462, ARV-766Phase 24 trials

    Novartis · Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic

  • ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials

    MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer

  • BalstilimabAGEN2034Phase 23 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • HRS-2189Phase 23 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Prostate Cancer

  • REGN5678NezastomigPhase 23 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • Teverelix DPPhase 23 trials

    Antev Ltd. · Acute Urinary Retention, Benign Prostate Hypertrophy(BPH), Endometriosis Pelvic

  • TulmimetostatDZR123, Tulmimetostat DL1Phase 23 trials

    Novartis · Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advanced Solid Tumor

  • AZD2287Imaging agentPhase 22 trials

    AstraZeneca · Metastatic Prostate Cancer

  • GI-102Phase 22 trials

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)

  • HRS-1167Phase 22 trials

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer

  • HRS-5041Phase 22 trials

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer

  • HRS-6208Phase 22 trials

    Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer of Adults, Prostate Cancer

  • MRT-2359Phase 22 trials

    Monte Rosa Therapeutics, Inc · Prostate Cancer, NSCLC, SCLC

  • QLH12016Phase 22 trials

    Qilu Pharmaceutical Co., Ltd. · Prostatic Neoplasms, Advanced Prostate Cancer

Page 1 of 2Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.